Skip to main content

Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.

Publication ,  Journal Article
Arnold, SD; Brazauskas, R; He, N; Li, Y; Aplenc, R; Jin, Z; Hall, M; Atsuta, Y; Dalal, J; Hahn, T; Khera, N; Bonfim, C; Majhail, NS; Saad, A ...
Published in: Haematologica
November 2017

Advances in allogeneic hematopoietic cell transplantation for sickle cell disease have improved outcomes, but there is limited analysis of healthcare utilization in this setting. We hypothesized that, compared to late transplantation, early transplantation (at age <10 years) improves outcomes and decreases healthcare utilization. We performed a retrospective study of children transplanted for sickle cell disease in the USA during 2000-2013 using two large databases. Univariate and Cox models were used to estimate associations of demographics, sickle cell disease severity, and transplant-related variables with mortality and chronic graft-versus-host disease, while Wilcoxon, Kruskal-Wallis, or linear trend tests were applied for the estimates of healthcare utilization. Among 161 patients with a 2-year overall survival rate of 90% (95% confidence interval [CI] 85-95%) mortality was significantly higher in those who underwent late transplantation versus early (hazard ratio (HR) 21, 95% CI 2.8-160.8, P=0.003) and unrelated compared to matched sibling donor transplantation (HR 5.9, 95% CI 1.7-20.2, P=0.005). Chronic graftversus host disease was significantly more frequent among those translanted late (HR 1.9, 95% CI 1.0-3.5, P=0.034) and those who received an unrelated graft (HR 2.5, 95% CI 1.2-5.4; P=0.017). Merged data for 176 patients showed that the median total adjusted transplant cost per patient was $467,747 (range: $344,029-$799,219). Healthcare utilization was lower among recipients of matched sibling donor grafts and those with low severity disease compared to those with other types of donor and disease severity types (P<0.001 and P=0.022, respectively); no association was demonstrated with late transplantation (P=0.775). Among patients with 2-year pre- and post-transplant data (n=41), early transplantation was associated with significant reductions in admissions (P<0.001), length of stay (P<0.001), and cost (P=0.008). Early transplant outcomes need to be studied prospectively in young children without severe disease and an available matched sibling to provide conclusive evidence for the superiority of this approach. Reduced post-transplant healthcare utilization inpatient care indicates that transplantation may provide a sustained decrease in healthcare costs over time.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Haematologica

DOI

EISSN

1592-8721

Publication Date

November 2017

Volume

102

Issue

11

Start / End Page

1823 / 1832

Location

Italy

Related Subject Headings

  • Young Adult
  • United States
  • Treatment Outcome
  • Treatment Failure
  • Transplantation, Homologous
  • Tissue Donors
  • Severity of Illness Index
  • Risk Assessment
  • Patient Acceptance of Health Care
  • Mortality
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Arnold, S. D., Brazauskas, R., He, N., Li, Y., Aplenc, R., Jin, Z., … Satwani, P. (2017). Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica, 102(11), 1823–1832. https://doi.org/10.3324/haematol.2017.169581
Arnold, Staci D., Ruta Brazauskas, Naya He, Yimei Li, Richard Aplenc, Zhezhen Jin, Matt Hall, et al. “Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.Haematologica 102, no. 11 (November 2017): 1823–32. https://doi.org/10.3324/haematol.2017.169581.
Arnold SD, Brazauskas R, He N, Li Y, Aplenc R, Jin Z, et al. Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica. 2017 Nov;102(11):1823–32.
Arnold, Staci D., et al. “Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.Haematologica, vol. 102, no. 11, Nov. 2017, pp. 1823–32. Pubmed, doi:10.3324/haematol.2017.169581.
Arnold SD, Brazauskas R, He N, Li Y, Aplenc R, Jin Z, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, Majhail NS, Diaz MA, Freytes CO, Wood WA, Savani BN, Kamble RT, Parsons S, Ahmed I, Sullivan K, Beattie S, Dandoy C, Munker R, Marino S, Bitan M, Abdel-Azim H, Aljurf M, Olsson RF, Joshi S, Buchbinder D, Eckrich MJ, Hashmi S, Lazarus H, Marks DI, Steinberg A, Saad A, Gergis U, Krishnamurti L, Abraham A, Rangarajan HG, Walters M, Lipscomb J, Saber W, Satwani P. Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica. 2017 Nov;102(11):1823–1832.

Published In

Haematologica

DOI

EISSN

1592-8721

Publication Date

November 2017

Volume

102

Issue

11

Start / End Page

1823 / 1832

Location

Italy

Related Subject Headings

  • Young Adult
  • United States
  • Treatment Outcome
  • Treatment Failure
  • Transplantation, Homologous
  • Tissue Donors
  • Severity of Illness Index
  • Risk Assessment
  • Patient Acceptance of Health Care
  • Mortality